Lilly Asia Ventures
Josh Jin, Ph.D., is a Senior Investment Manager with Lilly Asia Ventures (LAV). Prior to joining LAV, Josh was a Consultant at Boston Consulting Group (BCG) Shanghai office, helping biopharma companies and private equity firms on various corporate strategy and equity investment related topics. Prior to BCG, Josh worked at Syneos Health New York office as an Associate Consultant on pricing and market access. Josh holds Ph.D. in Genetics from Yale University and B.S. in Biotechnology from Fudan University.
This person is not in any offices
Lilly Asia Ventures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, they spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, they have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, they manage over $1.2 billion of committed capital.